IL-33/ST2 modulation therapy represents an emerging immunomodulatory approach for treating neurodegenerative diseases. Interleukin-33 (IL-33) is a member of the IL-1 family cytokine superfamily that functions as an alarmin — released upon cell damage to initiate protective immune responses["@cayrol2009"]. The IL-33/ST2 (IL-33 receptor) signaling axis plays complex roles in neuroinflammation, with both beneficial and pathogenic effects depending on disease context and stage.
Mechanism of Action
IL-33 Biology
IL-33 is constitutively expressed in the central nervous system, particularly in:
[Astrocytes](/entities/astrocytes): Primary source of IL-33 in the healthy brain
[Neurons](/entities/neurons): Express IL-33 particularly in hippocampal and cortical regions
[Microglia](/cell-types/microglia-neuroinflammation): Upregulate IL-33 in response to injury and disease
IL-33 acts as a dual-function cytokine:
Nuclear factor: Functions as a chromatin-associated nuclear protein that regulates gene expression
Cytokine: Released from damaged cells to activate immune responses through ST2 receptor[@gadina2012]
ST2 Receptor Signaling
The ST2 receptor (encoded by IL1RL1) exists in two forms:
Membrane-bound ST2 (ST2L): Expressed on various immune cells including mast cells, Th2 cells, macrophages, and neurons
Soluble ST2 (sST2): Decoy receptor that sequesters IL-33, modulating its activity
Amyloid pathology reduction: IL-33 administration reduces amyloid plaque burden in [APP](/entities/app-protein)/PS1 mice through enhanced microglial phagocytosis[@xiong2020]
Cognitive improvement: IL-33 treatment improves spatial memory in AD mouse models
Neuroinflammation reduction: Decreases pro-inflammatory cytokines (IL-1β, TNF-α) in brain tissue
Parkinson's Disease
DA neuron protection: IL-33 protects dopaminergic neurons in MPTP models
Glial modulation: Promotes anti-inflammatory phenotype in activated microglia
[α-synuclein](/proteins/alpha-synuclein) clearance: May enhance microglial clearance of α-synuclein aggregates
Amyotrophic Lateral Sclerosis (ALS)
Motor neuron protection: IL-33 shows protective effects in SOD1 mouse models
Glial response modulation: Reduces inflammatory activation of astrocytes and microglia
Clinical Development
Current Status
IL-33/ST2 modulation therapy remains in preclinical development for neurodegenerative diseases. No clinical trials have yet evaluated IL-33-based therapies specifically for AD, PD, or ALS.
Therapeutic Approaches
IL-33 Agonists:
Recombinant IL-33 protein administration
Small molecule ST2 agonists
Gene therapy approaches for sustained IL-33 expression
ST2 Antagonists:
Anti-ST2 antibodies (for diseases where IL-33 is pathogenic)
Soluble ST2 decoy proteins
Small molecule ST2 inhibitors
Challenges
Dose optimization: Balancing pro-inflammatory vs. anti-inflammatory effects
Delivery: Crossing the [blood-brain barrier](/entities/blood-brain-barrier) remains challenging
Disease stage: Timing of intervention may be critical
[Cayrol, C. & Girard, J.P, IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy (2009)](https://doi.org/10.1111/j.1398-9995.2009.02159.x)
[Gadina, M. & Schwartz, G, IL-33 as a novel therapeutic target (2012)](https://doi.org/10.1038/nri3112)
[Liu, Y. et al, IL-33 ameliorates Alzheimer's disease pathology by enhancing microglial phagocytosis of amyloid (2019)](https://doi.org/10.1038/s41598-019-56041-9)
[Xiong, Z. et al, IL-33 improves cognitive function and reduces neuroinflammation in APP/PS1 mice (2020)](https://pubmed.ncbi.nlm.nih.gov/32849756/)
[Fu, A.K. et al, IL-33 modulates neurodegeneration in a mouse model of Parkinson's disease (2019)](https://doi.org/10.1093/brain/awz139)
[Chaplin, D.D, Overview of the immune response (2010)](https://pubmed.ncbi.nlm.nih.gov/20176269/)
[Liew, F.Y., Girard, J.P. & Turnquist, H.R, IL-33 in health and disease (2016)](https://doi.org/10.1038/nri.2016.95)
[Licastro, F. et al, Polymorphic complement C3 and serum IL-1 receptor antagonist: major genetic modifiers of sporadic AD (2000)](https://pubmed.ncbi.nlm.nih.gov/10853843/)
[Shen, Y. et al, IL-33/ST2 signaling contributes to dopaminergic neuron injury in Parkinson's disease models (2020)](https://doi.org/10.1038/s41419-020-03021-6)
[Huang, H. et al, Targeting IL-33/ST2 signaling for neurodegenerative disease therapy (2021)](https://doi.org/10.1016/j.neuropharm.2021.108666)
[Sims, G.P. et al, IL-1 receptor antagonist as a therapeutic for Alzheimer's disease (2000)](https://pubmed.ncbi.nlm.nih.gov/11125144/)
[Smith, D.E. & Lipsky, P.E, Regulation of immune responses by IL-1 receptor antagonist (1993)](https://pubmed.ncbi.nlm.nih.gov/8434693/)
[Boutajangout, A. & Wisniewski, T, The use of CSF biomarkers to differentiate between Alzheimer's disease and other neurodegenerative disorders (2013)](https://pubmed.ncbi.nlm.nih.gov/24361108/)
[Eikelenboom, P. et al, The significance of neuroinflammation in Alzheimer's disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19428523/)
[Hennessy, E.J., Parker, A.E. & O'Neill, L.A, Targeting the IL-1/TLR signaling cascade in age-related disease (2010)](https://doi.org/10.1016/j.tips.2010.08.005)
Related Hypotheses
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate